What Boundless Bio does

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers. The company targets cancers characterized by extrachromosomal DNA (ecDNA), which is found in over 17% of solid tumors and underlies more than 25% of all cancers with oncogene amplifications — a population of more than 5 million newly diagnosed patients annually worldwide. Its core platform, Spyglass, is a proprietary drug discovery engine that combines cancer model systems, molecular analytical technologies, and data science to identify essential, druggable vulnerabilities unique to ecDNA-bearing cancer cells. ECHO, a proprietary software algorithm that detects ecDNA from routine clinical NGS data, is the first ecDNA diagnostic used in clinical trials for patient selection.

Boundless Bio's pipeline comprises three therapeutic programs targeting distinct ecDNA vulnerabilities: BBI-940, an oral kinesin degrader in Phase 1 development (KOMODO-1 trial) for ER+/HER2- breast cancer and TNBC-LAR subtypes, with preclinical single-agent tumor regressions; BBI-355, a CHK1 inhibitor targeting replication stress in oncogene amplified cancers; and RNR inhibitors designed to address ecDNA-mediated acquired resistance to KRAS inhibitors. The company is headquartered in San Diego, California, with scientific founders at Stanford, UCSD, and Scripps Research Institute, and trades on Nasdaq under ticker BOLD. In June 2026, Boundless Bio announced a definitive all-stock merger with privately held Serapha Bio, with the combined company to operate as Serapha Bio on Nasdaq under ticker AATD, focusing on gene editing therapy SERP-01 for alpha-1 antitrypsin deficiency.

As a pre-revenue clinical-stage biotechnology company, Boundless Bio's business model relies on equity financing to advance its pipeline through regulatory milestones, with future revenue contingent upon pharmaceutical product commercialization following regulatory approval. The company has raised approximately $251 million in cumulative equity financing (including a $100M Series C in May 2023) and a concurrent $230M PIPE financing tied to the Serapha merger, with Q1 2026 cash of $92.8M and a quarterly net loss of $13.6M. Go-to-market will be executed through traditional pharmaceutical commercialization pathways targeting oncologists and cancer treatment centers upon approval.

Name

Boundless Bio

Legal name

Boundless Bio, Inc.

Website

https://boundlessbio.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers, using its proprietary Spyglass platform and ECHO diagnostic to advance a pipeline including BBI-940 and BBI-355.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Precision oncology therapeutics
• EcDNA-directed therapies
• Oncogene amplified cancers
• Cancer drug discovery
• Targeted cancer therapies

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue clinical stage biotechnology company developing a pipeline of ecDNA-directed therapies for oncogene amplified cancers. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Boundless Bio develops ecDNA-directed therapies (ecDTx), a class of precision oncology therapeutics that exploit vulnerabilities specific to cancers driven by extrachromosomal DNA (ecDNA). Its pipeline includes BBI-940, an oral kinesin degrader currently in the Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes, as well as BBI-355 (a CHK1 inhibitor) and RNR inhibitor programs. Drug discovery is enabled by the proprietary Spyglass platform, and the proprietary ECHO diagnostic algorithm supports patient selection in clinical trials.

Product overview

Boundless Bio is a clinical-stage precision oncology company developing a pipeline of ecDNA-directed therapies (ecDTx) targeting oncogene amplified cancers. The company's core offerings include three therapeutic programs built on its proprietary Spyglass discovery platform: BBI-940 (lead kinesin degrader in Phase 1), BBI-355 (CHK1 inhibitor), and additional RNR inhibitor programs. The company also offers ECHO, a proprietary diagnostic algorithm that identifies ecDNA-bearing tumors using clinical NGS data to enable precision patient selection for its therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• BBI-940 Novel, oral, potent, and selective degrader of kinesin that targets ecDNA segregation in cancer cells; demonstrates robust anti-tumor activity and single-agent tumor regressions in preclinical cancer cell line and xenograft models. Currently in Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes.
• BBI-355 Checkpoint kinase 1 (CHK1) inhibitor targeting cancer cells with elevated replication stress due to high copy number gene amplifications on ecDNA. Developed as part of Boundless Bio's Replication Stress therapeutic approach for oncogene amplified cancers.
• ecDNA-directed therapies (ecDTx) Pipeline of next-generation precision oncology therapies designed to target and exploit vulnerabilities specific to oncogene amplified cancers driven by extrachromosomal DNA (ecDNA), covering three distinct therapeutic angles: DNA Segregation, Replication Stress, and DNA Assembly and Repair.

Quantifiable outcome

• Over 17% of patients with solid tumor have ecDNA in their cancer cells
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered major and core.

• Serapha BiomajorStrategic or Co-development Partner · 24 June 2026Boundless Bio and Serapha Bio entered into a definitive all-stock merger agreement in 2026. Boundless Bio shareholders expected to own approximately 3.7% of the combined company. Combined entity to operate under Serapha Bio name and trade on Nasdaq under ticker AATD, focusing on gene editing therapies.
• Stanford UniversitycoreStrategic or Co-development PartnerScientific co-founder Paul Mischel serves as Institute Scholar at Stanford University (ChEM-H) and Vice Chair of Research and Professor in the Dept of Pathology. Long-standing research collaboration in ecDNA biology.
• UC San DiegocoreStrategic or Co-development PartnerScientific co-founder Vineet Bafna is Professor of Computer Science & Engineering at UCSD. Company has deep ties to San Diego research ecosystem.
• The Scripps Research InstitutecoreStrategic or Co-development PartnerScientific co-founder Ben Cravatt is Professor and Gilula Chair of Chemical Biology at The Scripps Research Institute. Academic collaboration in chemical biology and drug discovery.
• YolTech TherapeuticsmajorTechnology or IntegrationSerapha Bio entered a licensing agreement with Shanghai-based YolTech Therapeutics for worldwide rights to SERP-01 (in vivo base editing therapy) outside Greater China, in exchange for undisclosed upfront payment and minority equity stake. This is part of the merged entity's pipeline.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Black Diamond Therapeutics: Clinical-stage precision oncology company developing small molecule therapies against oncogenic drivers; comparable to Boundless Bio in stage, public-market profile, and focus on genomically-defined cancer populations.
• Repare Therapeutics: Precision oncology company leveraging synthetic lethality and genome-wide CRISPR screens to develop targeted cancer therapies; highly comparable mechanism-discovery approach to Boundless Bio's Spyglass platform and clinical-stage profile.
• Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design against oncogenic targets; similar stage, public-market status, and precision-oncology positioning to Boundless Bio.
• Erasca: Precision oncology company developing therapies targeting the RAS/MAPK pathway in oncogene-driven cancers; directly comparable in patient population (oncogene-amplified/activated tumors) and clinical stage.
• Nuvalent: Clinical-stage precision oncology company designing kinase inhibitors for genomically-defined cancers; comparable in oncology indication focus, public-market profile, and target-discovery approach.
• IDEAYA Biosciences: Precision oncology biotech developing synthetic lethality and targeted therapies for biomarker-selected patient populations; closely matches Boundless Bio's precision-medicine model and clinical-stage profile.
• Tango Therapeutics: Clinical-stage synthetic lethality-focused precision oncology company leveraging CRISPR-based target discovery; highly comparable to Boundless Bio's platform-driven approach and patient-selection strategy.
• Foghorn Therapeutics: Clinical-stage oncology biotech developing medicines targeting chromatin biology and dysregulated gene expression; comparable in platform-driven precision oncology approach and clinical-stage status.

Emerging players

• Crinetics Pharmaceuticals: Clinical-stage precision medicine company developing targeted therapies; provides a comparable model of a San Diego-based precision therapeutics biotech with similar public-company growth trajectory.

Others

• Ignyta: Acquired precision oncology company whose lead asset Rozlytrek was developed by Boundless CEO Zachary Hornby as COO before Ignyta's $2B sale to Roche; relevant as a comparable successful exit and as a talent pedigree benchmark.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/boundlessbio
• Xx.com/BoundlessBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boundless Bio